[go: up one dir, main page]

IS7593A - Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum - Google Patents

Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum

Info

Publication number
IS7593A
IS7593A IS7593A IS7593A IS7593A IS 7593 A IS7593 A IS 7593A IS 7593 A IS7593 A IS 7593A IS 7593 A IS7593 A IS 7593A IS 7593 A IS7593 A IS 7593A
Authority
IS
Iceland
Prior art keywords
hsf
gram
negative bacteria
antigens
transferrin protein
Prior art date
Application number
IS7593A
Other languages
English (en)
Inventor
Jacques Berthet Francois-Xavier
Biemans Ralph
Denoel Philippe
Feron Christiane
Goraj Carine
Poolman Jan
Weynants Vincent
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31722002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0218037A external-priority patent/GB0218037D0/en
Priority claimed from GB0218036A external-priority patent/GB0218036D0/en
Priority claimed from GB0218051A external-priority patent/GB0218051D0/en
Priority claimed from GB0218035A external-priority patent/GB0218035D0/en
Priority claimed from GBGB0220197.8A external-priority patent/GB0220197D0/en
Priority claimed from GBGB0220199.4A external-priority patent/GB0220199D0/en
Priority claimed from GB0225531A external-priority patent/GB0225531D0/en
Priority claimed from GB0225524A external-priority patent/GB0225524D0/en
Priority claimed from GB0230164A external-priority patent/GB0230164D0/en
Priority claimed from GB0230170A external-priority patent/GB0230170D0/en
Priority claimed from GB0230168A external-priority patent/GB0230168D0/en
Priority claimed from GB0305028A external-priority patent/GB0305028D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of IS7593A publication Critical patent/IS7593A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7593A 2002-08-02 2004-12-13 Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum IS7593A (is)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0218036A GB0218036D0 (en) 2002-08-02 2002-08-02 Vaccine
GB0218051A GB0218051D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218035A GB0218035D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218037A GB0218037D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GBGB0220197.8A GB0220197D0 (en) 2002-08-30 2002-08-30 Refolding method
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
GB0225531A GB0225531D0 (en) 2002-11-01 2002-11-01 Vaccine
GB0225524A GB0225524D0 (en) 2002-11-01 2002-11-01 Vaccine composition
GB0230164A GB0230164D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0230170A GB0230170D0 (en) 2002-12-24 2002-12-24 Vaccine
GB0230168A GB0230168D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0305028A GB0305028D0 (en) 2003-03-05 2003-03-05 Vaccine
PCT/EP2003/008567 WO2004014419A1 (en) 2002-08-02 2003-07-31 Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria

Publications (1)

Publication Number Publication Date
IS7593A true IS7593A (is) 2004-12-13

Family

ID=31722002

Family Applications (3)

Application Number Title Priority Date Filing Date
IS7593A IS7593A (is) 2002-08-02 2004-12-13 Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum
IS7601A IS7601A (is) 2002-08-02 2004-12-16 Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum
IS7658A IS7658A (is) 2002-08-02 2005-01-20 Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu

Family Applications After (2)

Application Number Title Priority Date Filing Date
IS7601A IS7601A (is) 2002-08-02 2004-12-16 Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum
IS7658A IS7658A (is) 2002-08-02 2005-01-20 Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu

Country Status (25)

Country Link
US (9) US20060057160A1 (is)
EP (11) EP1524992B1 (is)
JP (7) JP2006506467A (is)
KR (6) KR20050028051A (is)
CN (2) CN1674933B (is)
AU (6) AU2003269864A1 (is)
CA (4) CA2493977A1 (is)
CO (3) CO5680454A2 (is)
CY (3) CY1114243T1 (is)
DE (2) DE20321889U1 (is)
DK (2) DK1524993T3 (is)
ES (3) ES2575014T3 (is)
HU (1) HUE029200T2 (is)
IL (3) IL165660A0 (is)
IS (3) IS7593A (is)
LU (1) LU92262I2 (is)
MX (3) MXPA05001265A (is)
MY (1) MY149591A (is)
NO (3) NO20050010L (is)
NZ (4) NZ537904A (is)
PL (5) PL216662B1 (is)
PT (2) PT1524993E (is)
SI (2) SI2255826T1 (is)
TW (1) TWI360424B (is)
WO (4) WO2004014418A2 (is)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US10967045B2 (en) * 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
CA2838395C (en) * 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
MXPA02004283A (es) 1999-10-29 2002-10-17 Chiron Spa Peptidos antigenicos neisseriales.
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2398139A1 (en) * 2000-01-25 2001-08-02 The University Of Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha
EP1261723B1 (en) 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybrid expression of neisserial proteins
US6936261B2 (en) * 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
JP4592284B2 (ja) 2001-07-27 2010-12-01 カイロン ソチエタ ア レスポンサビリタ リミタータ 髄膜炎菌付着因子
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
MY149591A (en) * 2002-08-02 2013-09-13 Glaxosmithkline Biolog Sa Vaccines comprising l2 and/or l3 los from neisseria
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK1549338T3 (da) * 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
AU2004274977B2 (en) 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
BRPI0415025A (pt) 2003-10-02 2006-12-12 Chiron Srl vacinas lìquidas para sorogrupos meningocócicos múltiplos
GB0323709D0 (en) * 2003-10-09 2003-11-12 Health Prot Agency Modified whole cell,cell extract and omv-based vaccines
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
JP5174457B2 (ja) * 2004-05-11 2013-04-03 デ スタート デール ネーダーランデン， フェルテヘンウォールディヒィト ドール デ ミニステール ファン フォルクスヘーゾンドハイド， フェルザイン アン スポルト アジュバントとしての髄膜炎菌ｌｇｔＢＬＯＳ
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
GB0428381D0 (en) * 2004-12-24 2005-02-02 Isis Innovation Vaccine
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
ES2588010T3 (es) 2005-01-21 2016-10-28 Epitopix, Llc Polipéptidos de Yersinia spp. y métodos de uso
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
PE20070163A1 (es) 2005-06-27 2007-03-01 Glaxosmithkline Biolog Sa Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7955817B2 (en) 2005-09-02 2011-06-07 Glaxosmithkline Biologicals S.A. Vaccine protection assay
EP2208999B1 (en) 2005-09-05 2014-08-27 GlaxoSmithKline Biologicals SA Serum bactericidal assay for N. meningitidis specific antisera
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20110008279A1 (en) * 2005-12-06 2011-01-13 Vega Masignani Methods and Compositions Relating to Adhesins as Adjuvants
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
EA015833B1 (ru) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
EP2032161B1 (en) * 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
AU2007293672B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ ヌクレオチド糖の改良製造法
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US20100285465A1 (en) * 2007-08-02 2010-11-11 Glaxosmithkline Biologicals S.A. Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis
ES2383231T3 (es) 2007-10-19 2012-06-19 Novartis Ag Formulaciones para vacunas meningocócicas
EP2886551A3 (en) * 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
KR20110053314A (ko) * 2008-05-30 2011-05-20 더 유에스에이, 애즈 리프리젠티드 바이 더 세크리터리 오브 더 아미, 온 비하프 오브 월터 리드 아미 수막구균성 다가 천연 외막 소포체 백신, 이의 제조 방법 및 사용 방법
KR101042541B1 (ko) * 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 ｇ（－） 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법
WO2010027729A2 (en) * 2008-08-25 2010-03-11 Creatv Microtech, Inc. Gonococcal vaccines
GB0816447D0 (en) 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
CN101759781B (zh) * 2008-12-25 2013-04-03 上海市第六人民医院 一种细菌表层黏附蛋白及其用途
MX2011006903A (es) 2008-12-25 2011-09-15 Chemo Sero Therapeut Res Inst Vacuna recombinante de coriza infecciosa aviar y procedimiento para preparar la misma.
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
BRPI1009828A2 (pt) 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica
EP2411044A2 (en) * 2009-03-24 2012-02-01 Novartis AG Combinations including pneumococcal serotype 14 saccharide
CN102438649A (zh) 2009-03-24 2012-05-02 诺华有限公司 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
EP2430151B1 (fr) 2009-05-14 2014-06-18 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
NZ597004A (en) * 2009-05-14 2013-03-28 Sanofi Pasteur Method for admixing the lipopolysaccharide (lps) of gram-negative bacteria
NZ597008A (en) * 2009-05-14 2013-03-28 Sanofi Pasteur Meningococcal vaccine based on lipooligosaccharide (los) and neisseria meningitidis protein
WO2010134225A1 (ja) * 2009-05-20 2010-11-25 国立大学法人鳥取大学 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
CN102480932B (zh) 2009-09-01 2015-01-14 阿昂梅迪克斯公司 源于肠道共生细菌的细胞外小泡及利用其的疫苗、备选药物筛选方法
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
GB0917002D0 (en) * 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
EP2496597A4 (en) * 2009-11-06 2013-08-14 Childrens Hosp & Res Ct Oak T CELL STIMULATING PROTEIN B AND METHOD FOR ITS USE
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
US9365624B2 (en) * 2010-03-11 2016-06-14 Glaxosmithkline Biologicals, S.A. Vaccine
JP2013522287A (ja) 2010-03-18 2013-06-13 ノバルティス アーゲー 血清群ｂ髄膜炎菌のためのアジュバント添加ワクチン
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
AU2011235296C1 (en) * 2010-03-29 2017-05-04 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
AU2013202310C1 (en) * 2010-03-29 2017-01-05 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
WO2012032498A2 (en) 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CN103228787B (zh) * 2010-09-28 2017-06-23 阿贝拉生物科学公司 用于分泌性蛋白表达的融合蛋白
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
TR201808206T4 (tr) * 2011-07-07 2018-07-23 De Staat Der Nederlanden Vert Door De Mini Van Vws Bir gram negatif bakterinin dış membran veziküllerinin deterjan içermeyen üretimi prosesi.
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
WO2013113917A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
JP5698693B2 (ja) * 2012-03-13 2015-04-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ
JP2015521595A (ja) 2012-06-14 2015-07-30 ノバルティス アーゲー 血清群ｘ髄膜炎菌のためのワクチン
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
CN105163724A (zh) 2013-02-07 2015-12-16 葛兰素史密丝克莱恩生物有限公司 包含囊泡的药物组合物
WO2014138290A1 (en) * 2013-03-05 2014-09-12 Trudeau Institute, Inc. Compositions and methods for treating bacterial infections
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
SMT202000704T1 (it) 2014-02-28 2021-01-05 Glaxosmithkline Biologicals Sa POLIPEPTIDI DI fHbp DI MENINGOCOCCO MODIFICATI
US10232029B2 (en) 2014-12-09 2019-03-19 Sanofi Pasteur Compositions comprising N. meningitidis proteins
EP3838918B1 (en) 2015-05-18 2022-08-31 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
AU2018206552C1 (en) 2017-01-04 2025-04-10 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CN112823038B (zh) 2018-10-05 2025-10-03 国家儿童医院研究所 用于移除生物膜的hmgb1蛋白衍生物
JP7469302B2 (ja) * 2018-11-06 2024-04-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US12005110B2 (en) 2019-02-14 2024-06-11 University Of Florida Research Foundation, Incorporated Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202203250D0 (en) 2022-03-09 2022-04-20 Glaxosmithkline Biologicals Sa Immunogenic compositions
CN119792504A (zh) * 2023-10-10 2025-04-11 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239746A (en) * 1973-06-30 1980-12-16 Dezso Istvan Bartos Complement fixation test employing reactants in a disposable package
DE2744721A1 (de) 1977-10-05 1979-04-19 Veba Chemie Ag Pulverfoermige ueberzugsmittel und deren anwendung
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US20020146764A1 (en) * 1985-03-28 2002-10-10 Chiron Corporation Expression using fused genes providing for protein product
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3622221A1 (de) * 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DK0539492T3 (da) 1990-07-16 2003-09-22 Univ North Carolina Antigene jernundertrykkelige proteiner fra N. meningitidis beslægtet med hemolysinfamilien af toksiner
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
ES2210228T3 (es) 1990-08-23 2004-07-01 University Of North Carolina At Chapel Hill Proteinas de union a transferrina de neisseria gonorrhoeae y neisseria meningitidis.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5371186A (en) 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
US5652211A (en) 1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
DE69227898T2 (de) * 1991-03-14 1999-05-12 Imclone Systems, Inc., New York, N.Y. Rekombinante hybride porinepitope
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
CA2127871A1 (en) 1992-01-13 1993-07-22 Andreas Herman Hogt Crosslinking of rubbers with engineering plastics
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6358727B1 (en) 1993-11-08 2002-03-19 Aventis Pasteur Limited Haemophilus transferrin receptor genes
US6361779B1 (en) 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6287574B1 (en) * 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
AU700080B2 (en) 1995-06-07 1998-12-17 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the HSP70 family
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
WO1997010844A1 (en) * 1995-09-18 1997-03-27 United States Army Medical Research Materiel Command (Usamrmc) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
US6440701B1 (en) 1996-03-08 2002-08-27 Aventis Pasteur Limited Transferrin receptor genes of Moraxella
ES2262177T3 (es) 1996-05-01 2006-11-16 The Rockefeller University Proteinas de union a colina para vacunas frente a neumococos.
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
JP2001502925A (ja) 1997-06-03 2001-03-06 コノート ラボラトリーズ リミテッド モラクセラのラクトフェリン受容体遺伝子
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
WO1999006781A1 (de) 1997-07-31 1999-02-11 Wilo Gmbh Latentwärmespeicher für ein kraftfahrzeug
ES2275314T3 (es) 1997-08-15 2007-06-01 Rijksuniversiteit Utrecht Proteina de neisseria de union a lactoferrina.
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
ES2333071T5 (es) * 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
CA2325340A1 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
GB9809683D0 (en) 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9811260D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
TR200003608T2 (tr) 1998-06-03 2001-04-20 Smithkline Beecham Biologicals S.A. Moraxella Catarrhalis'e ait BASB027 proteinleri ve genleri.
GB9812163D0 (en) 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9814902D0 (en) 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US6951652B2 (en) 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
GB9820003D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9820002D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
NZ511540A (en) * 1998-10-09 2004-05-28 Chiron Corp Neisseria genomic sequences and methods of their use
CA2345903C (en) 1998-10-16 2006-09-26 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Molecular pathogenicide mediated plant disease resistance
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
EP1127137B2 (en) 1998-11-03 2013-12-25 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria
DE60042114D1 (de) * 1999-04-30 2009-06-10 Craig J Venter Inst Inc Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
WO2000066741A2 (en) * 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
CA2838395C (en) * 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
AU1824101A (en) 1999-06-18 2001-01-09 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome
GB2351515B (en) 1999-06-29 2002-09-11 Pandrol Ltd Adjustable railway rail fastening assembly and methods for use therewith
GB9917977D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9918038D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9918302D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9918208D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
CA2390344C (en) 1999-11-29 2014-08-26 Chiron Spa 85kda neisserial antigen
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
CA2398139A1 (en) * 2000-01-25 2001-08-02 The University Of Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha
EP1261723B1 (en) * 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybrid expression of neisserial proteins
GB0007432D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
US6936261B2 (en) * 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
JP4592284B2 (ja) * 2001-07-27 2010-12-01 カイロン ソチエタ ア レスポンサビリタ リミタータ 髄膜炎菌付着因子
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003028661A2 (en) 2001-10-03 2003-04-10 Chiron Corporation Adjuvanted meningococcus compositions
MY149591A (en) * 2002-08-02 2013-09-13 Glaxosmithkline Biolog Sa Vaccines comprising l2 and/or l3 los from neisseria
DK1549338T3 (da) * 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0315021D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BRPI0415025A (pt) * 2003-10-02 2006-12-12 Chiron Srl vacinas lìquidas para sorogrupos meningocócicos múltiplos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
US8039007B2 (en) * 2006-06-29 2011-10-18 J. Craig Venter Institute, Inc. Polypeptides from Neisseria meningitidis

Also Published As

Publication number Publication date
IL166433A0 (en) 2006-01-15
JP5414651B2 (ja) 2014-02-12
PL399214A1 (pl) 2012-11-19
CO5680455A2 (es) 2006-09-29
MXPA05001349A (es) 2005-04-28
EP2258384A3 (en) 2011-12-28
US20060240045A1 (en) 2006-10-26
IL213264A0 (en) 2011-07-31
JP2011051997A (ja) 2011-03-17
EP1524991A1 (en) 2005-04-27
US20060051379A1 (en) 2006-03-09
AU2003250204A1 (en) 2004-02-25
JP2011142916A (ja) 2011-07-28
AU2008202479B2 (en) 2011-09-22
EP1524993B1 (en) 2013-03-06
AU2003260357B2 (en) 2009-10-29
AU2008202479C1 (en) 2014-01-16
EP2258386A2 (en) 2010-12-08
KR20120036996A (ko) 2012-04-18
US8221770B2 (en) 2012-07-17
KR20110036642A (ko) 2011-04-07
TW200408406A (en) 2004-06-01
CN1671413A (zh) 2005-09-21
DK1524993T3 (da) 2013-06-03
PL216662B1 (pl) 2014-04-30
WO2004014419A1 (en) 2004-02-19
US20120064120A1 (en) 2012-03-15
US20110033500A1 (en) 2011-02-10
JP2006500963A (ja) 2006-01-12
JP2006505628A (ja) 2006-02-16
ES2575014T3 (es) 2016-06-23
SI1524993T1 (sl) 2013-07-31
EP2258385A2 (en) 2010-12-08
US20120027800A1 (en) 2012-02-02
AU2003260357A1 (en) 2004-02-25
WO2004014418A2 (en) 2004-02-19
JP2012107036A (ja) 2012-06-07
EP1524993A2 (en) 2005-04-27
JP2006506467A (ja) 2006-02-23
DE20321889U1 (de) 2012-03-12
NZ537904A (en) 2008-03-28
WO2004015099A3 (en) 2004-04-22
MY149591A (en) 2013-09-13
EP2258384A2 (en) 2010-12-08
AU2008202479A1 (en) 2008-06-26
NZ587398A (en) 2012-03-30
CY2013036I1 (el) 2015-12-09
CO5680454A2 (es) 2006-09-29
EP1961427A2 (en) 2008-08-27
KR101139976B1 (ko) 2012-05-08
WO2004014418A3 (en) 2004-07-22
PL375382A1 (en) 2005-11-28
KR20080078082A (ko) 2008-08-26
MXPA05000842A (es) 2005-04-28
ES2537737T3 (es) 2015-06-11
IL166433A (en) 2011-08-31
NO20050008L (no) 2005-04-28
PL375408A1 (en) 2005-11-28
EP1524992B1 (en) 2015-03-04
AU2003269864A1 (en) 2004-02-25
PL220107B1 (pl) 2015-08-31
IS7601A (is) 2004-12-16
US20120064119A1 (en) 2012-03-15
EP2255826B1 (en) 2016-04-13
EP1524992A2 (en) 2005-04-27
WO2004014417A2 (en) 2004-02-19
IS7658A (is) 2005-01-20
JP4740738B2 (ja) 2011-08-03
NZ537181A (en) 2007-01-26
EP2255826A2 (en) 2010-12-01
MXPA05001265A (es) 2005-04-28
CA2493092A1 (en) 2004-02-19
CA2489030A1 (en) 2004-02-19
DK2255826T3 (en) 2016-06-20
AU2003253375A1 (en) 2004-02-25
JP5409986B2 (ja) 2014-02-05
US20160082097A1 (en) 2016-03-24
US7838014B2 (en) 2010-11-23
LU92262I2 (fr) 2013-09-30
KR101239242B1 (ko) 2013-03-11
KR101140033B1 (ko) 2012-05-07
DE20321890U1 (de) 2012-03-12
EP2258386A3 (en) 2011-11-02
AU2003250204B2 (en) 2008-06-19
KR20050042143A (ko) 2005-05-04
KR20050039839A (ko) 2005-04-29
EP2481419A2 (en) 2012-08-01
AU2003250204B8 (en) 2008-07-10
CY1117643T1 (el) 2017-04-26
KR20050028051A (ko) 2005-03-21
CY1114243T1 (el) 2015-12-09
NO20050421L (no) 2005-03-30
PL375407A1 (en) 2005-11-28
CA2493124A1 (en) 2004-02-19
HK1077014A1 (en) 2006-02-03
JP2006500962A (ja) 2006-01-12
EP2481419A3 (en) 2013-04-10
CA2493977A1 (en) 2004-02-19
CA2493124C (en) 2014-04-29
ES2408251T3 (es) 2013-06-19
NZ574530A (en) 2010-12-24
AU2008255270A1 (en) 2009-01-08
IL165660A0 (en) 2006-01-15
WO2004014417A3 (en) 2004-07-22
HUE029200T2 (en) 2017-03-28
EP1524990A2 (en) 2005-04-27
EP1961427A3 (en) 2009-11-04
JP5789203B2 (ja) 2015-10-07
PL399492A1 (pl) 2012-11-19
SI2255826T1 (sl) 2016-07-29
US20060034854A1 (en) 2006-02-16
TWI360424B (en) 2012-03-21
PT1524993E (pt) 2013-06-12
PT2255826E (pt) 2016-06-08
CN1674933A (zh) 2005-09-28
EP2255826A3 (en) 2012-03-28
CN1674933B (zh) 2012-09-26
EP2258387A2 (en) 2010-12-08
EP2258385A3 (en) 2012-01-18
US20060057160A1 (en) 2006-03-16
KR101237329B1 (ko) 2013-02-28
NO20050010L (no) 2005-02-09
WO2004015099A2 (en) 2004-02-19
CO5680456A2 (es) 2006-09-29
CY2013036I2 (el) 2015-12-09
EP2258387A3 (en) 2011-10-19
AU2003253375B2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
IS7593A (is) Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
DK1373301T3 (da) Reducering af immunogeniciteten af fusionsproteiner
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
DK1235589T3 (da) Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen
GB0103424D0 (en) Gonococcus proteins
EP2341062A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP1594560A4 (en) COMPOSITIONS, METHODS AND KITS FOR INCREASING THE IMMUNOGENICITY OF A BACTERIA VACCINE VECTOR
ATE388230T1 (de) Neisseria meningitidis antigene und zusammenstellungen
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
ATE269104T1 (de) Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert
EA200702254A1 (ru) Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
WO2006113907A3 (en) Escherichia coli o157:h7 proteins and uses thereof
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
GB0409559D0 (en) Polypeptide
PT1535928E (pt) Composições de vacina compreendendo proteínas omp85 de neisseria gonorrhoeae e neisseria meningitidis
WO2002067982A3 (en) Mycobacterial vaccines
Pichichero et al. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan